Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 8.39B P/E 202.35 EPS this Y -52.00% Ern Qtrly Grth -
Income -1.3B Forward P/E 38.78 EPS next Y 214.60% 50D Avg Chg 8.00%
Sales 4.1B PEG 3.55 EPS past 5Y 2.55% 200D Avg Chg -10.00%
Dividend N/A Price/Book 1.78 EPS next 5Y 32.82% 52W High Chg -60.00%
Recommedations 2.60 Quick Ratio 1.50 Shares Outstanding 180.97M 52W Low Chg 48.00%
Insider Own 0.50% ROA -0.75% Shares Float 179.72M Beta 1.19
Inst Own 111.15% ROE -30.28% Shares Shorted/Prior 7.19M/7.85M Price 46.54
Gross Margin 17.94% Profit Margin -31.77% Avg. Volume 4,534,559 Target Price 56.70
Oper. Margin -8.01% Earnings Date May 17 Volume 1,895,705 Change 0.06%
About Catalent, Inc.

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Catalent, Inc. News
04/25/24 TAK or CTLT: Which Is the Better Value Stock Right Now?
04/11/24 Charles River (CRL) Forges Collaboration With Ship of Theseus
04/08/24 Novo Nordisk parent refiles US application on Catalent deal
04/08/24 UPDATE 1-Novo Nordisk parent refiles US application on Catalent deal
04/05/24 Ares, Blue Owl Lead $4.8 Billion Private Debt for Catalent Deal
03/28/24 13 Hot Stocks to Invest in According to Wall Street Analysts
03/09/24 The Top 3 Pharma Stocks to Buy in March 2024
03/08/24 HIGHLIGHTS-Novo Nordisk hopes to launch experimental obesity drug this decade
03/07/24 Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
02/10/24 Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
02/09/24 Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
02/09/24 Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
02/09/24 UPDATE 3-Catalent sales edge past estimates as focus shifts to Novo deal
02/09/24 Catalent Inc (CTLT) Faces Headwinds with Q2 Fiscal 2024 Results
02/09/24 Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
02/08/24 UPDATE 2-Astrazeneca says Catalent deal shows need for in-house capacity
02/08/24 Astrazeneca says Catalent deal shows need for in-house capacity
02/07/24 UPDATE 1-US FDA finds control lapses at Catalent plant being sold to Novo
02/07/24 UPDATE 2-EU watchdog looking into impact on drug availability from Catalent-Novo deal
02/07/24 Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
CTLT Chatroom

User Image CruzinC Posted - 2 weeks ago

$CTLT get back to $60 so I can take a nice profit, jeez 😂

User Image Theflash88 Posted - 2 weeks ago

$CTLT $NVO X is another one.. I think it will go through.. will watch carefully.. $55 buyout price.

User Image Theflash88 Posted - 2 weeks ago

$CTLT $NVO Agree but i think it will close near end of the year.

User Image insiderbuyingselling Posted - 1 month ago

$CTLT new insider selling: 387 shares. http://insiderbuyingselling.com/?t=CTLT

User Image jewell69 Posted - 1 month ago

@Theflash88 $CTLT WHERE did you find this 12/31/24 expected closing date ?

User Image jewell69 Posted - 1 month ago

$CTLT arbitrage; worth it. when might it close Catalent entered into a merger agreement with Novo Nordisk’s parent company on Feb 5. Per the agreement, NVO’s parent company will acquire all outstanding shares of Catalent for $63.50 per share in cash. The deal values Catalent at $16.5 billion on an enterprise value basis. 3/8/23 close 56.51 12.36% discount to 63.50 $NVO

User Image jewell69 Posted - 1 month ago

$CTLT 2/7/24 $NVO Denmark-based Novo said in January that it had begun boosting supplies of Wegovy in the United States, after curtailing starting doses last year to ensure there would be enough for existing patients. Then in February, Novo’s controlling shareholder acquired Catalent, a manufacturer based in New Jersey, an unusual move that would give the drugmaker three new manufacturing plants. REMEMBER ARMAGEDDON DAY ON CTLT 4/13/23 CLOSE 53.31 4/14/23 CLOSE 46.32 AND ONE MORE ... 5/5 47.75 5/6 35.46 REMEMBER THESE TRADES ? 05/19/2023 09:43:50 Sold 26 CTLT @ 35.675 927.54 0.00 0.01 05/09/2023 15:59:18 Bought 26 CTLT @ 35.04 -911.04 0.00 0.00 05/09/2023 09:05:18 Sold 25 CTLT @ 35.69 892.24 0.00 0.01 05/08/2023 16:03:34 Bought 25 CTLT @ 35.46 -911.50

User Image Stock_Titan Posted - 1 month ago

$CTLT Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment https://www.stocktitan.net/news/CTLT/catalent-publishes-fifth-annual-corporate-responsibility-report-3gyavc90l9oi.html

User Image Aigner_Andreas Posted - 1 month ago

TF SELL $CTLT at 56.65 : 56.76 BigCap 50% Shp 2.56 S 6.99 N 1.12 RSI 55.49% SRSI 0% ADXR 38.4 #stocks #trading #finance #market

User Image swingingtech Posted - 1 month ago

$LLY $NVO $CTLT https://wallstreetwaves.com/escalating-demand-for-obesity-drugs-creates-time-sensitive-race-for-eli-lilly-novo-nordisk/

User Image Mergerbrief Posted - 1 month ago

$CTLT Novo Holdings - HSR filed By Date MergerBrief.com

User Image Marketoverview Posted - 02/28/24

$CTLT Cash merger is looking good, If you are looking for more Merger Arbitrage deals checkout our website https://marketoverview-app.com/mergerarbitragescreener

User Image Investor6 Posted - 1 month ago

$WX $CTLT https://www.thebell.co.kr/free/content/ArticleView.asp?key=202402191343391800104022&lcode=00

User Image MilkOnion Posted - 2 months ago

$CTLT PT by March 15? Asking for a friend

User Image NancyBaird641 Posted - 2 months ago

$CTLT excels in drug delivery, but COEP's cell therapy initiatives are groundbreaking, promising a new era in cancer treatment.

User Image swingingtech Posted - 2 months ago

$CTLT https://wallstreetwaves.com/ctlt-crosses-above-average-analyst-target/

User Image Theflash88 Posted - 2 months ago

$CTLT Buyout isn’t until the end of the year! I’m not tying up my money for that long.

User Image Sliver Posted - 2 months ago

$CTLT has been a great play from the low 40s and now assessing best buyout details. Early calls paid well.

User Image MilkOnion Posted - 2 months ago

$CTLT https://www.webullapp.com/news-detail/10224255831376896?theme=1&hl=en&color=2&_v=1&tickerId=913254636&disSymbol=CTLT&sp=0&hl=en

User Image MilkOnion Posted - 2 months ago

$CTLT what the heck happened today, why no movement ?

User Image BlondeAmbition Posted - 2 months ago

$CTLT $NVO

User Image CTFNLighthouse Posted - 2 months ago

$CTLT $NVO $LLY The US Federal Trade Commission is expected to look closely at the ability of Eli Lilly and other drugmakers to find alternate suppliers of manufacturing services if Novo Holdings and Novo Nordisk acquire Catalent’s facilities, CTFN reported, citing to industry specialists and antitrust attorneys.

User Image Theflash88 Posted - 2 months ago

$CTLT I’ll patiently wait for my $63.50 a share..

User Image MilkOnion Posted - 2 months ago

$CTLT why is it hardly moving

User Image DonCorleone77 Posted - 2 months ago

$CTLT Catalent reports Q2 EPS (24c), consensus (2c) Reports Q2 revenue $1.03B, consensus $1.01B. "I am proud of the progress the Catalent team made in our second quarter and our ongoing momentum, including strong non-COVID sequential revenue growth in both the Biologics and PCH segments. We also continued to invest in our operational improvement initiatives and areas of high growth," said Alessandro Maselli, president and CEO of Catalent. "Our commitment to providing customers with premium development and manufacturing solutions is our north star and our recently announced transaction with Novo Holdings is further proof of that. With the benefit of Novo Holdings' expanded resources, we will be able to accelerate investment in our business and enhance key offerings for current and prospective pharma and biotech customers. Indeed, we remain focused on continuing to serve our valued customers, as we always have."

User Image epsguid Posted - 2 months ago

$CTLT reported a loss of $0.33, consensus was ($0.06) via @eWhispers #epsmiss http://eps.sh/d/ctlt

User Image Stock_Titan Posted - 2 months ago

$CTLT Catalent, Inc. Reports Second Quarter Fiscal 2024 Results https://www.stocktitan.net/news/CTLT/catalent-inc-reports-second-quarter-fiscal-2024-mpy2cvvdk9kg.html

User Image Hardtobeagod Posted - 2 months ago

$CTLT what time is the report ?

User Image MilkOnion Posted - 2 months ago

$CTLT PT for tomorrow?

User Image Mergerbrief Posted - 2 months ago

$CTLT $TFII Reports Earnings Mergerbrief.com

Analyst Ratings
Stephens & Co. Equal-Weight Apr 4, 24
RBC Capital Sector Perform Feb 20, 24
RBC Capital Sector Perform Feb 6, 24
UBS Neutral Feb 6, 24
Stephens & Co. Equal-Weight Feb 6, 24
Barclays Equal-Weight Jan 25, 24
RBC Capital Outperform Nov 16, 23
Wells Fargo Equal-Weight Nov 16, 23
Baird Outperform Nov 16, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GREISCH JOHN J Executive Chair Executive Chair Aug 30 Buy 50.24 21,000 1,055,040 34,000 09/01/23
Maselli Alessandro President & CEO President & CEO Aug 23 Sell 44.83 2,071 92,843 88,004 08/25/23
Gunther Scott SVP, Quality & Reg... SVP, Quality & Reg. Affairs Aug 23 Sell 44.57 269 11,989 29,932 08/25/23
Grippo Michael J SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. Aug 23 Sell 44.5 390 17,355 24,449 08/25/23
Gennadios Aristippos Group Pres. Pharma &.. Group Pres. Pharma & Consumer Aug 23 Sell 44.49 396 17,618 96,552 08/25/23
Fasman Steven L EVP & Chief Admin Of.. EVP & Chief Admin Officer Aug 23 Sell 44.65 817 36,479 73,789 08/25/23
Carletti Lorenzo SVP Global Ops Ph &.. SVP Global Ops Ph & Cons Hlth Aug 23 Sell 44.71 216 9,657 8,746 08/25/23
Arnold Jonathan SVP, CCO & Div. Head.. SVP, CCO & Div. Head BioP Del. Aug 23 Sell 44.87 87 3,904 57,399 08/25/23
Hopson Ricky Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div Aug 23 Sell 44.56 276 12,299 22,040 08/25/23
Hawkeswood Thomas W Pres. Pharma Prod De.. Pres. Pharma Prod Delivery Div Aug 23 Sell 44.72 147 6,574 7,533 08/25/23
Lickfold Charles SVP, CIO SVP, CIO Aug 23 Sell 44.72 190 8,497 11,339 08/25/23
Hunt Patricia Pres. Consumer Healt.. Pres. Consumer Health Div Aug 23 Sell 44.77 106 4,746 11,289 08/25/23
Pravda Ricardo Chief Transformation.. Chief Transformation Officer Aug 23 Sell 44.47 379 16,854 30,224 08/25/23
Pravda Ricardo Chief Transformation.. Chief Transformation Officer Aug 01 Sell 47.14 269 12,681 19,739 08/03/23
Maselli Alessandro President & CEO President & CEO Aug 01 Sell 47.23 1,485 70,137 86,101 08/03/23
Lickfold Charles SVP, CIO SVP, CIO Aug 01 Sell 47.9 135 6,466 5,570 08/03/23
Fasman Steven L EVP & Chief Admin Of.. EVP & Chief Admin Officer Aug 01 Sell 47.24 1,637 77,332 60,216 08/03/23
Boerman Manja Pres. BioModalities.. Pres. BioModalities Division May 01 Sell 49.86 1,446 72,098 14,414 05/03/23
Hopson Ricky Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div Jan 23 Sell 49.36 643 31,738 16,452 01/25/23
Boerman Manja Pres. BioModalities.. Pres. BioModalities Division Dec 05 Sell 51.70 780 40,326 15,860 12/07/22
Grippo Michael J SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. Oct 31 Sell 65.83 2,451 161,349 17,792 11/02/22
Hopson Ricky Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div Aug 31 Sell 89.59 2,216 198,531 17,095 09/02/22
Riley Michael A. Pres. Bio Product De.. Pres. Bio Product Delivery Div Aug 26 Sell 104.07 2,491 259,238 6,592 08/30/22
Gunther Scott SVP, Quality & Reg... SVP, Quality & Reg. Affairs Aug 26 Sell 104.07 1,639 170,571 23,988 08/30/22
Schmidt Kay A SVP, Enterprise Func.. SVP, Enterprise Functions Aug 24 Sell 103.04 1,321 136,116 17,388 08/26/22
Riley Michael A. Pres. Bio Product De.. Pres. Bio Product Delivery Div Aug 24 Sell 103.04 1,482 152,705 9,083 08/26/22
Pravda Ricardo SVP & Chief HR Offic.. SVP & Chief HR Officer Aug 24 Sell 103.04 1,747 180,011 20,008 08/26/22
Maselli Alessandro President & CEO President & CEO Aug 24 Sell 103.04 4,646 478,724 41,190 08/26/22
Hunt Patricia Pres. Consumer Healt.. Pres. Consumer Health Div Aug 24 Sell 103.04 339 34,931 9,315 08/26/22
Hopson Ricky Pres. Clinical Dev S.. Pres. Clinical Dev Supply Div Aug 24 Sell 103.04 1,517 156,312 19,311 08/26/22
Hawkeswood Thomas W Pres. Pharma Prod De.. Pres. Pharma Prod Delivery Div Aug 24 Sell 103.04 671 69,140 6,294 08/26/22
Gunther Scott SVP, Quality & Reg... SVP, Quality & Reg. Affairs Aug 24 Sell 103.04 1,840 189,594 25,627 08/26/22
Grippo Michael J SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. Aug 24 Sell 103.04 1,670 172,077 20,243 08/26/22
Gennadios Aristippos Group Pres. Pharma &.. Group Pres. Pharma & Consumer Aug 24 Sell 103.04 1,645 169,501 86,769 08/26/22
Gargiulo Mario SVP Global Ops Biolo.. SVP Global Ops Biologics Aug 24 Sell 103.04 1,586 163,421 6,354 08/26/22
Fasman Steven L EVP & Chief Admin Of.. EVP & Chief Admin Officer Aug 24 Sell 103.04 4,811 495,725 61,853 08/26/22
Chiminski John R Executive Chair Executive Chair Aug 24 Sell 103.04 38,934 4,011,759 229,888 08/26/22
Castellano Thomas P SVP, Chief Financial.. SVP, Chief Financial Officer Aug 24 Sell 103.04 1,414 145,699 20,099 08/26/22
Carletti Lorenzo SVP Global Ops Ph &.. SVP Global Ops Ph & Cons Hlth Aug 24 Sell 103.04 1,033 106,440 4,985 08/26/22
Boerman Manja Pres. BioModalities.. Pres. BioModalities Division Aug 24 Sell 103.04 3,296 339,620 16,640 08/26/22
Arnold Jonathan SVP & Chief Commerci.. SVP & Chief Commercial Ofcr Aug 24 Sell 103.04 384 39,567 55,958 08/26/22
Schmidt Kay A SVP, Enterprise Func.. SVP, Enterprise Functions Jul 26 Sell 106.9 323 34,529 13,455 07/28/22
Pravda Ricardo SVP & Chief HR Offic.. SVP & Chief HR Officer Jul 26 Sell 106.9 427 45,646 15,337 07/28/22
Maselli Alessandro President & CEO President & CEO Jul 26 Sell 106.9 816 87,230 25,083 07/28/22
Hopson Ricky Pres, Clinical Dev &.. Pres, Clinical Dev & Supply Jul 26 Sell 107.29 903 96,883 17,095 07/28/22
Gunther Scott SVP, Quality & Reg... SVP, Quality & Reg. Affairs Jul 26 Sell 107.29 844 90,553 22,350 07/28/22
Grippo Michael J SVP, Strategy & Corp.. SVP, Strategy & Corp. Dev. Jul 26 Sell 107.29 797 85,510 17,023 07/28/22
Gennadios Aristippos Group Pres. Pharma &.. Group Pres. Pharma & Consumer Jul 26 Sell 106.9 403 43,081 79,784 07/28/22
Gargiulo Mario SVP Global Ops Biolo.. SVP Global Ops Biologics Jul 26 Sell 106.9 969 103,586 3,671 07/28/22
Fasman Steven L EVP & Chief Admin Of.. EVP & Chief Admin Officer Jul 26 Sell 106.9 2,546 272,167 53,721 07/28/22